nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-2CF9DED5·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Physiology·Basis: Full text·Type: Observational study

Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study.

Patel et al.Patel, Feng, Mckay et al.·2026·The Lancet. Neurology·10.1016/s1474-4422(26)00123-7 ↗

Primary claim

Three genome-wide loci with significant risk were associated with ADAD risk, irrespective of the specific ADAD gene mutation.

Tentative · non-carrier controls and gene-concentrated alleles do not establish mutation-independent modifier effects
In brief

A hypothesis-generating ADAD GWAS identifies promising modifier candidates, but its carrier-versus-non-carrier design cannot establish mutation-independent effects.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Abstract

BACKGROUND: Individuals with autosomal dominant Alzheimer's disease (ADAD) arising from mutations in PSEN1, PSEN2, or APP exhibit variability in clinical presentation. Genetic studies of ADAD have shaped our understanding of the disease, and the discovery of genetic modifiers can inform therapeutic interventions and improve patient outcomes. We aimed to discover new genetic modifiers in individuals with mutations in the three ADAD genes.

METHODS: In this genome-wide association study, we analysed data from participants in three study cohorts (the Knight Alzheimer Disease Research Center [Knight-ADRC], the Dominantly Inherited Alzheimer Network [DIAN] observational study, and the Alzheimer Disease Sequencing Project [ADSP] R4). We did whole-genome sequencing on 101 unrelated, non-Hispanic, White, symptomatic participants with ADAD mutations and 5050 asymptomatic, unrelated control participants. Sensitivity analyses included related participants (148 cases and 5813 controls). We assessed the molecular mechanisms associated with each risk variant, including cis-regulatory effects, plasma protein levels (Knight-ADRC, 2338 participants), CSF concentrations of Alzheimer's disease biomarkers (DIAN, 64 participants), and neuroimaging data (MRI and PET; DIAN, 64 participants). We evaluated the association of risk variants with age at onset in ADAD and in 6177 participants with sporadic Alzheimer's disease (ADSP R5).

FINDINGS: Three genome-wide loci with significant risk were associated with ADAD risk, irrespective of the specific ADAD gene mutation. The CNIH4 locus association was driven by a missense variant (is caused by Gly54Ser, p<0·0001, odds ratio [OR] 11·99 [5·39-26·64]). The CCNG1 locus risk allele increased the risk of Alzheimer's disease (p<0·0001, OR 9·56 [4·29-21·24]) and reduced the age at dementia onset (p=0·0068, β=-10·15 [95% CI -17·31 to -2·77]). This allele was also positively associated with Tar DNA binding protein 43 (TDP-43) plasma protein levels and a larger gap between chronological age and structural MRI predicted brain age. The RHOJ risk allele (p<0·0001, OR 5·96 [3·42-10·36]) was associated with increased the risk of Alzheimer's disease, higher CSF total tau (p=0·0056, β=358·37) and phosphorated tau 181 (pTau181; p=0·0006, β=81·28), and lower Aβ42/Aβ40 ratio (p=0·016, β=-0·11) in DIAN ADAD participants, comparing those carrying the risk allele with those not carrying it.

INTERPRETATION: Our findings provide potential insights into disease biology, emphasising the role of Aβ, tau, TDP-43, astrocytes, and angiogenesis in Alzheimer's disease aetiology. This study offers invaluable insight for family genetic counselling and future clinical trial designs.

FUNDING: National Institute of Health, National Institute on Aging, Alzheimer's Association, Hope Center Pilot 2025 Award, NGI Pilot Grant 2025 Award, BrightFocus Foundation, UK Dementia Research Institute at University College London, UK National Institutes for Health and Care Research University College London Hospitals Biomedical Research Centre, Dominantly Inherited Alzheimer Network, Freedom Together Foundation.

Key Claims

Primary finding · Tentative

Three genome-wide loci with significant risk were associated with ADAD risk, irrespective of the specific ADAD gene mutation.

non-carrier controls and gene-concentrated alleles do not establish mutation-independent modifier effects

Abstract, Findings
Quote verified
Secondary · Tentative

The CCNG1 variant is associated with earlier onset, potentially through the acceleration of pathogenic processes such as TDP-43 aggregation

the onset association rests on nine carriers and the proposed TDP-43 mechanism remains unestablished

Discussion, summary paragraph
Quote verified
Secondary · Tentative

The RHOJ variant is associated with CSF Alzheimer’s disease biomarkers

the small biomarker analysis lacks disease-stage adjustment and described multiplicity control

Discussion, summary paragraph
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Broad ADAD modifier research question

The study combines Knight-ADRC, DIAN, and ADSP data to investigate modifier signals across APP, PSEN1, and PSEN2 mutation carriers rather than focusing on one family alone.

↳ Introduction, paragraphs 2–4; Methods, Study Design and Participants

#methodological rigour

Multiple sensitivity and replication analyses

The GWAS uses Firth regression, adjusts for cohort and ancestry components, repeats sentinel-variant analyses with related participants using SAIGE, and tests an independent ADSP R5 cohort.

↳ Methods, Genome-Wide Association Analysis

#contribution

Layered functional phenotype follow-up

The study evaluates age at onset, plasma proteins, cis-regulatory evidence, CSF biomarkers, and neuroimaging phenotypes, generating specific hypotheses around CCNG1, RHOJ, and CNIH4.

↳ Methods, Protein QTL through Neuroimaging Analyses; Results, functional-characterisation paragraphs

Limitations

#methodological rigour

Modifier interpretation remains structurally confounded

Cases are symptomatic ADAD mutation carriers, while controls are non-carriers; the design therefore cannot cleanly distinguish disease modification from mutation or lineage background. The uneven allele distribution by ADAD gene makes this concern material.

↳ Methods, Study Design and Participants; Results, GWAS paragraph reporting carrier counts

#contribution

Replication and carrier counts are limited

CCNG1 and CNIH4 each involve nine discovery carriers, and only RHOJ reaches nominal significance in the 34-case replication cohort. CCNG1 remains only nearly genome-wide significant in the combined meta-analysis.

↳ Results, GWAS and replication paragraph

#positioning

Key limitation omitted from discussion

The limitations section addresses power, winner’s curse, and ancestry but not the use of non-carrier controls or the possibility of mutation- or lineage-linked signals. This omission leaves the central modifier claim insufficiently qualified.

↳ Discussion, limitations paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

The study addresses a meaningful gap in ADAD genetics and uses several appropriate analytical tools, including Firth regression, related-participant sensitivity analysis, independent replication, and multi-omic follow-up. Its central inference is nevertheless limited by comparing symptomatic mutation carriers with non-carriers, while the reported risk alleles are concentrated within particular ADAD gene groups. This design issue is more consequential than the otherwise strong formal analysis and keeps the work in the hypothesis-generating range. Partial replication, imprecise genome-wide p-value reporting, and small secondary analyses further limit clinical interpretation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.8±0.2

Contribution
3.3

The study extends ADAD modifier research across three cohorts and adds genetic, biomarker, proteomic, and imaging hypotheses. Its contribution remains preliminary because independent replication is limited and the rare signals involve few carriers.

Methods, Genome-Wide Association Analysis; Results, GWAS and functional-characterisation paragraphs

In the replication analysis in 34 unrelated ADAD case participants... RHOJ showed nominal significance.

Methodological Rigour
2.5

Firth regression, ancestry and cohort adjustment, related-participant sensitivity analysis, and independent replication are appropriate analytic elements. However, comparing symptomatic mutation carriers with non-carriers does not isolate modifier effects from mutation or lineage background, particularly given the allele distribution by ADAD gene.

Methods, Study Design and Participants and Genome-Wide Association Analysis; Results, GWAS paragraph

Nine participants carried the risk allele at the CNIH4 locus, with two carrying a PSEN1 mutation and seven a PSEN2 mutation.

Reporting
3.2

The paper follows a coherent progression from GWAS discovery through functional follow-up and clinical phenotypes. The headline phrase “irrespective of the specific ADAD gene mutation” is stronger than the sparse and uneven cross-gene carrier evidence permits.

Abstract, Findings; Results, GWAS paragraph

irrespective of the specific ADAD gene mutation

Positioning
2.8

The Introduction situates the study among APOE Christchurch, RELN, SNX25, fibronectin, and other modifier work, while the Discussion acknowledges sample size, winner’s curse, and ancestry. It does not address the decisive limitation created by non-carrier controls and mutation- or lineage-linked allele distributions.

Introduction, paragraphs 2–4; Discussion, limitations paragraph

our analysis is based on participants of European descent

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

Principal association probabilities are reported as p<0·0001, which is insufficiently precise to confirm the stated genome-wide significance threshold but does not contradict it.

Conflict of interest: not stated · Ethics approval: declared · Data availability: declared · Code availability: not stated

Reference IntegrityClean

31 references in manuscript 31 of 31 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

Independent replication in 34 ADAD cases was nominal for RHOJ only; CNIH4 and CCNG1 significance rests on pooled discovery data.

From the paper
“These genetic variants could help family genetic counselling and future clinical trial designs.”

Names family genetic counselling and future trial design as settings, but does not specify the decisions or how the variants would be applied.

Pathway

Genetic counsellors and clinical trial designers could use these variants to inform family risk counselling and stratify ADAD participants in trials.

Barrier

Replication is weak: 34 ADAD cases, nominal for one locus only, no independent confirmation of CNIH4 or CCNG1, and European-only samples limit generalisability.

Evaluated 13 Nov 2026 · GBD 2023 · haiku_fallback_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →